# Neuropace Inc. (NPCE) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $12.31, market value $423 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Neuropace Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 4.3×**. Each dollar of revenue is priced at 4.3×.
- **Price / book: 35.5×**. The shares trade at 35.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.7%** (5-yr avg -26.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 79.6%**. Neuropace Inc. keeps 79.6% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -15.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -21.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -112.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -21.2%**. Return on all capital, debt included, is -21.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -18.1%**. Each dollar of assets produces -18.1% of profit.

## Growth
- **Revenue growth (1 yr): 25.1%** (3-yr 30.0%/yr, 5-yr 19.4%/yr). Revenue grew 25.1% over the last year, against 19.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 29.0%**. Earnings per share rose 29.0%, roughly in step with revenue.

## Financial health
- **Debt to equity: 3.09**. Debt is 3.09 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Current ratio: 5.28** (quick 5.28). Current assets cover the next year's liabilities 5.28 times.
- **Altman Z-score: 4.49**. A Z-score of 4.49 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Neuropace Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Neuropace Inc.; the consensus is strong_buy, with an average price target of $20.00 (+62% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.0%** (YTD -20.3%, 3-mo -12.9%). The shares are up 31.0% over twelve months including dividends.
- **From 52-week high: -37.2%** (14.3% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 1.42** (volatility 63%). Beta of 1.42 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NPCE · Page: https://foliofundamentals.com/stocks/npce

Not investment advice.